March 10, 2022
Kala Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that UnitedHealthcare has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022.
Kala also announced that Cigna Medicare has added EYSUVIS as a preferred brand effective February 2022. EYSUVIS now has Medicare preferred coverage for select plans with Express Scripts, Prime Therapeutics and Cigna.
“Today’s announcement marks significant progress toward our goal of expanding access to EYSUVIS for the millions of people who suffer from dry eye disease, including dry eye flares,” said Todd Bazemore, president and chief operating officer of Kala Pharmaceuticals. “We look forward to continuing to engage with other commercial and Medicare Part D health plans as we execute on our goal of providing broad market access to EYSUVIS for eyecare professionals and their patients.”
Other Articles to Explore
EYSUVIS became commercially available in January 2021 as an FDA-approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
For full prescribing information, visit www.eysuvis.com.
